Concord Biotech gains on clearing PPB Kenya, NDA Uganda inspection at Unit-II formulation facility
Concord Biotech is currently trading at Rs. 1291.95, up by 3.30 points or 0.26% from its previous closing of Rs. 1288.65 on the BSE.
The scrip opened at Rs. 1294.85 and has touched a high and low of Rs. 1320.50 and Rs. 1283.75 respectively. So far 6259 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1979.20 on 24-Jul-2025 and a 52 week low of Rs. 987.05 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1377.95 and Rs. 1283.50 respectively. The current market cap of the company is Rs. 13499.15 crore.
The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 17.02% and 38.90% respectively.
Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully.
The successful completion of PPB and NDA inspection marks a significant step in the company’s global growth journey. This achievement reinforces its commitment to the highest standards of quality and regulatory excellence while strengthening its global manufacturing and regulatory footprint.
